BioDiem

BioDiem is an Australian biopharmaceutical company dedicated to the development and commercialization of vaccines and infectious disease treatments. BDM-I is BioDiem's novel antibacterial compound for treating severe human infections. The compound is active against a range of pathogenic microorganisms and is protected by global patents. BioDiem’s subsidiary, Opal Biosciences Ltd, was established to develop the BDM-I technology, enabling external investment in the project and helping to fast-track BDM-I research.